Probiotic use in at-risk populations

Mary Ellen Sanders, Daniel J. Merenstein, Arthur C. Ouwehand, Gregor Reid, Seppo Salminen, Michael D. Cabana, George Paraskevakos, Gregory Leyer

Research output: Contribution to journalComment/debate

33 Citations (Scopus)

Abstract

Objective To inform health care providers about quality standards for manufacture of probiotic products being recommended for at-risk patient populations. Summary Probiotics are used in a variety of clinical settings, sometimes in at-risk populations for therapeutic endpoints. Although probiotics might not be approved as drugs, they are sometimes used for the prevention or treatment of disease. In the United States, and many regions of the world, probiotic products are marketed as dietary supplements (not drugs) and are therefore subject to different manufacturing and quality control standards than approved drugs are. Health care providers need to be assured that probiotic products used in at-risk populations are safe for this use. Pharmacists should require certificates of analysis, which document quality standards, from manufacturers of products stocked in hospital formularies or other pharmacies dispensing to at-risk people. Although responsible manufacturers use stringent quality standards on their processes and finished products, using a third party to verify compliance with manufacturing and accuracy of product labeling adds assurance to end users that the product is of high quality. Conclusion It is in patients’ best interest to use probiotics in the prevention and treatment of conditions when the evidence is convincing. To protect high-risk patients, probiotic products should meet stringent microbiological standards. Product testing results should be available for review before recommending probiotic products to at-risk individuals. For products used in at-risk populations, manufacturers should provide this information or participate in a third-party verification program that certifies compliance.

Original languageEnglish (US)
Pages (from-to)680-686
Number of pages7
JournalJournal of the American Pharmacists Association
Volume56
Issue number6
DOIs
StatePublished - Nov 1 2016
Externally publishedYes

Fingerprint

Probiotics
Health care
Health Personnel
Hospital Formularies
Dietary supplements
Pharmaceutical Preparations
Product Labeling
Pharmacies
Dietary Supplements
Pharmacists
Quality Control
Labeling
Compliance
Quality control
Therapeutics
Testing

ASJC Scopus subject areas

  • Pharmacology (nursing)
  • Pharmacy
  • Pharmacology

Cite this

Sanders, M. E., Merenstein, D. J., Ouwehand, A. C., Reid, G., Salminen, S., Cabana, M. D., ... Leyer, G. (2016). Probiotic use in at-risk populations. Journal of the American Pharmacists Association, 56(6), 680-686. https://doi.org/10.1016/j.japh.2016.07.001

Probiotic use in at-risk populations. / Sanders, Mary Ellen; Merenstein, Daniel J.; Ouwehand, Arthur C.; Reid, Gregor; Salminen, Seppo; Cabana, Michael D.; Paraskevakos, George; Leyer, Gregory.

In: Journal of the American Pharmacists Association, Vol. 56, No. 6, 01.11.2016, p. 680-686.

Research output: Contribution to journalComment/debate

Sanders, ME, Merenstein, DJ, Ouwehand, AC, Reid, G, Salminen, S, Cabana, MD, Paraskevakos, G & Leyer, G 2016, 'Probiotic use in at-risk populations', Journal of the American Pharmacists Association, vol. 56, no. 6, pp. 680-686. https://doi.org/10.1016/j.japh.2016.07.001
Sanders ME, Merenstein DJ, Ouwehand AC, Reid G, Salminen S, Cabana MD et al. Probiotic use in at-risk populations. Journal of the American Pharmacists Association. 2016 Nov 1;56(6):680-686. https://doi.org/10.1016/j.japh.2016.07.001
Sanders, Mary Ellen ; Merenstein, Daniel J. ; Ouwehand, Arthur C. ; Reid, Gregor ; Salminen, Seppo ; Cabana, Michael D. ; Paraskevakos, George ; Leyer, Gregory. / Probiotic use in at-risk populations. In: Journal of the American Pharmacists Association. 2016 ; Vol. 56, No. 6. pp. 680-686.
@article{4421b232371842fa99e8a12035fd9a0c,
title = "Probiotic use in at-risk populations",
abstract = "Objective To inform health care providers about quality standards for manufacture of probiotic products being recommended for at-risk patient populations. Summary Probiotics are used in a variety of clinical settings, sometimes in at-risk populations for therapeutic endpoints. Although probiotics might not be approved as drugs, they are sometimes used for the prevention or treatment of disease. In the United States, and many regions of the world, probiotic products are marketed as dietary supplements (not drugs) and are therefore subject to different manufacturing and quality control standards than approved drugs are. Health care providers need to be assured that probiotic products used in at-risk populations are safe for this use. Pharmacists should require certificates of analysis, which document quality standards, from manufacturers of products stocked in hospital formularies or other pharmacies dispensing to at-risk people. Although responsible manufacturers use stringent quality standards on their processes and finished products, using a third party to verify compliance with manufacturing and accuracy of product labeling adds assurance to end users that the product is of high quality. Conclusion It is in patients’ best interest to use probiotics in the prevention and treatment of conditions when the evidence is convincing. To protect high-risk patients, probiotic products should meet stringent microbiological standards. Product testing results should be available for review before recommending probiotic products to at-risk individuals. For products used in at-risk populations, manufacturers should provide this information or participate in a third-party verification program that certifies compliance.",
author = "Sanders, {Mary Ellen} and Merenstein, {Daniel J.} and Ouwehand, {Arthur C.} and Gregor Reid and Seppo Salminen and Cabana, {Michael D.} and George Paraskevakos and Gregory Leyer",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.japh.2016.07.001",
language = "English (US)",
volume = "56",
pages = "680--686",
journal = "Journal of the American Pharmacists Association : JAPhA",
issn = "1544-3191",
publisher = "American Pharmacists Association",
number = "6",

}

TY - JOUR

T1 - Probiotic use in at-risk populations

AU - Sanders, Mary Ellen

AU - Merenstein, Daniel J.

AU - Ouwehand, Arthur C.

AU - Reid, Gregor

AU - Salminen, Seppo

AU - Cabana, Michael D.

AU - Paraskevakos, George

AU - Leyer, Gregory

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Objective To inform health care providers about quality standards for manufacture of probiotic products being recommended for at-risk patient populations. Summary Probiotics are used in a variety of clinical settings, sometimes in at-risk populations for therapeutic endpoints. Although probiotics might not be approved as drugs, they are sometimes used for the prevention or treatment of disease. In the United States, and many regions of the world, probiotic products are marketed as dietary supplements (not drugs) and are therefore subject to different manufacturing and quality control standards than approved drugs are. Health care providers need to be assured that probiotic products used in at-risk populations are safe for this use. Pharmacists should require certificates of analysis, which document quality standards, from manufacturers of products stocked in hospital formularies or other pharmacies dispensing to at-risk people. Although responsible manufacturers use stringent quality standards on their processes and finished products, using a third party to verify compliance with manufacturing and accuracy of product labeling adds assurance to end users that the product is of high quality. Conclusion It is in patients’ best interest to use probiotics in the prevention and treatment of conditions when the evidence is convincing. To protect high-risk patients, probiotic products should meet stringent microbiological standards. Product testing results should be available for review before recommending probiotic products to at-risk individuals. For products used in at-risk populations, manufacturers should provide this information or participate in a third-party verification program that certifies compliance.

AB - Objective To inform health care providers about quality standards for manufacture of probiotic products being recommended for at-risk patient populations. Summary Probiotics are used in a variety of clinical settings, sometimes in at-risk populations for therapeutic endpoints. Although probiotics might not be approved as drugs, they are sometimes used for the prevention or treatment of disease. In the United States, and many regions of the world, probiotic products are marketed as dietary supplements (not drugs) and are therefore subject to different manufacturing and quality control standards than approved drugs are. Health care providers need to be assured that probiotic products used in at-risk populations are safe for this use. Pharmacists should require certificates of analysis, which document quality standards, from manufacturers of products stocked in hospital formularies or other pharmacies dispensing to at-risk people. Although responsible manufacturers use stringent quality standards on their processes and finished products, using a third party to verify compliance with manufacturing and accuracy of product labeling adds assurance to end users that the product is of high quality. Conclusion It is in patients’ best interest to use probiotics in the prevention and treatment of conditions when the evidence is convincing. To protect high-risk patients, probiotic products should meet stringent microbiological standards. Product testing results should be available for review before recommending probiotic products to at-risk individuals. For products used in at-risk populations, manufacturers should provide this information or participate in a third-party verification program that certifies compliance.

UR - http://www.scopus.com/inward/record.url?scp=84994462053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994462053&partnerID=8YFLogxK

U2 - 10.1016/j.japh.2016.07.001

DO - 10.1016/j.japh.2016.07.001

M3 - Comment/debate

C2 - 27836128

AN - SCOPUS:84994462053

VL - 56

SP - 680

EP - 686

JO - Journal of the American Pharmacists Association : JAPhA

JF - Journal of the American Pharmacists Association : JAPhA

SN - 1544-3191

IS - 6

ER -